The required "medication assessed" component needs to be able to have a recommendation proposal from the lab. Each medication assessed for a given derived pgx genotype or complex diplotype finding that has a metabolic, transporter or efficacy impact should also be able to have a text and url recommendation. Many PGX results show several drug-recommendations for a single PGX metab, efficacy or transporter impact.

For example

CYP2C19 *2/*2 may be a Poor Metabolizer for the following

1) clipidogrel - https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/ - lab text abstract of interp/recommendation
2) voriconaxzole - https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/ - Lab text abstract of this
3) citalopram, escitalopram - https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/ - lab abstract
4)amitriptyline , etc..

...